Free Trial
Chardan Capital

Chardan Capital Analyst Recommendations & Stock Picks

View the latest stock recommendations issued by analysts at Chardan Capital. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from Chardan Capital's equity research team. MarketBeat is not affiliated with or endorsed by Chardan Capital.

Average Return
00.00% 12-Month ROI
Total Ratings
306 Last 12 Months
Buy Ratings
288 Last 12 Months
Sell Ratings
0 Last 12 Months
Companies Covered
79 Last 12 Months
MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
CompanyCurrent PriceReport DateAnalystActionPrice TargetRating12-Month Recommendation ROIDetails
Kodiak AI, Inc. stock logo
KDK
Kodiak AI
$7.24
-0.1%
5/8/2026Lower Price Target$22.00 ➝ $15.00BuyView details for Chardan Capital rating of Kodiak AI (NASDAQ:KDK) on 5/8/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$3.62
5/7/2026Lower Price Target$16.00 ➝ $14.00BuyView details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 5/7/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
$11.37
5/5/2026Initiated Coverage$22.00BuyView details for Chardan Capital rating of Climb Bio (NASDAQ:CLYM) on 5/5/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$3.11
5/5/2026Boost Price Target$3.50 ➝ $4.00BuyView details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 5/5/2026
Galaxy Digital Inc. stock logo
GLXY
Galaxy Digital
$30.23
5/4/2026Reiterated Rating$35.00BuyView details for Chardan Capital rating of Galaxy Digital (NASDAQ:GLXY) on 5/4/2026
Keel Infrastructure stock logo
KEEL
Keel Infrastructure
$3.97
5/4/2026UpgradeStrong-BuyView details for Chardan Capital rating of Keel Infrastructure (NASDAQ:KEEL) on 5/4/2026
Riot Platforms, Inc. stock logo
RIOT
Riot Platforms
$24.08
5/4/2026UpgradeStrong-BuyView details for Chardan Capital rating of Riot Platforms (NASDAQ:RIOT) on 5/4/2026
uniQure N.V. stock logo
QURE
uniQure
$27.66
4/30/2026Boost Price Target$31.00 ➝ $37.00BuyView details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 4/30/2026
Riot Platforms, Inc. stock logo
RIOT
Riot Platforms
$24.08
4/27/2026Initiated Coverage$27.50BuyView details for Chardan Capital rating of Riot Platforms (NASDAQ:RIOT) on 4/27/2026
Galaxy Digital Inc. stock logo
GLXY
Galaxy Digital
$30.23
4/27/2026Initiated Coverage$35.00BuyView details for Chardan Capital rating of Galaxy Digital (NASDAQ:GLXY) on 4/27/2026
Keel Infrastructure stock logo
KEEL
Keel Infrastructure
$3.97
4/27/2026Initiated Coverage$4.50BuyView details for Chardan Capital rating of Keel Infrastructure (NASDAQ:KEEL) on 4/27/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$14.09
4/27/2026Boost Price Target$27.00 ➝ $30.00BuyView details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 4/27/2026
VinFast Auto Ltd. stock logo
VFS
VinFast Auto
$4.31
4/23/2026Reiterated Rating$5.50BuyView details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 4/23/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$24.26
0.0%
4/22/2026Reiterated Rating$30.00BuyView details for Chardan Capital rating of Alto Neuroscience (NYSE:ANRO) on 4/22/2026
Passage Bio, Inc. stock logo
PASG
Passage Bio
$4.21
4/21/2026Set Price Target$21.00 ➝ $7.00BuyNeutralView details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 4/21/2026
Passage Bio, Inc. stock logo
PASG
Passage Bio
$4.21
4/21/2026Downgrade$21.00 ➝ $7.00BuyHoldView details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 4/21/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$3.62
4/10/2026Reiterated Rating$16.00BuyView details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 4/10/2026
iBio, Inc. stock logo
IBIO
iBio
$1.71
4/9/2026Reiterated Rating$5.00BuyView details for Chardan Capital rating of iBio (NASDAQ:IBIO) on 4/9/2026
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
$1.58
4/9/2026Reiterated Rating$4.00BuyView details for Chardan Capital rating of ProQR Therapeutics (NASDAQ:PRQR) on 4/9/2026
Cleanspark, Inc. stock logo
CLSK
Cleanspark
$14.20
4/8/2026Reiterated Rating$16.00BuyView details for Chardan Capital rating of Cleanspark (NASDAQ:CLSK) on 4/8/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$24.26
0.0%
4/2/2026Reiterated Rating$30.00BuyView details for Chardan Capital rating of Alto Neuroscience (NYSE:ANRO) on 4/2/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$121.29
3/31/2026Boost Price Target$210.00 ➝ $240.00BuyView details for Chardan Capital rating of Palvella Therapeutics (NASDAQ:PVLA) on 3/31/2026
Alumis Inc. stock logo
ALMS
Alumis
$23.66
3/30/2026Reiterated Rating$38.00BuyView details for Chardan Capital rating of Alumis (NASDAQ:ALMS) on 3/30/2026
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
$63.58
3/30/2026Reiterated Rating$100.00BuyView details for Chardan Capital rating of Monopar Therapeutics (NASDAQ:MNPR) on 3/30/2026
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
$0.99
3/30/2026Lower Price Target$13.00 ➝ $11.00BuyView details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 3/30/2026
ZOOZ Power Ltd. stock logo
ZOOZ
ZOOZ Power
$0.29
3/30/2026Reiterated Rating$2.00BuyView details for Chardan Capital rating of ZOOZ Power (NASDAQ:ZOOZ) on 3/30/2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
$1.21
3/27/2026Reiterated Rating$4.00BuyView details for Chardan Capital rating of Cognition Therapeutics (NASDAQ:CGTX) on 3/27/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$9.82
3/27/2026Reiterated Rating$35.00BuyView details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 3/27/2026
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
$3.63
3/27/2026Reiterated Rating$11.00BuyView details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 3/27/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$295.05
3/25/2026Reiterated Rating$425.00BuyView details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 3/25/2026
Kodiak AI, Inc. stock logo
KDK
Kodiak AI
$7.24
-0.1%
3/25/2026Reiterated Rating$22.00BuyView details for Chardan Capital rating of Kodiak AI (NASDAQ:KDK) on 3/25/2026
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.51
3/25/2026Reiterated Rating$7.00BuyView details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 3/25/2026
Zura Bio Limited stock logo
ZURA
Zura Bio
$4.79
3/23/2026Boost Price Target$10.00 ➝ $11.00BuyView details for Chardan Capital rating of Zura Bio (NASDAQ:ZURA) on 3/23/2026
Alumis Inc. stock logo
ALMS
Alumis
$23.66
3/20/2026Boost Price Target$37.00 ➝ $38.00BuyView details for Chardan Capital rating of Alumis (NASDAQ:ALMS) on 3/20/2026
Annexon, Inc. stock logo
ANNX
Annexon
$5.69
3/20/2026Reiterated Rating$16.00BuyView details for Chardan Capital rating of Annexon (NASDAQ:ANNX) on 3/20/2026
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$7.27
3/20/2026Reiterated Rating$15.00BuyView details for Chardan Capital rating of Solid Biosciences (NASDAQ:SLDB) on 3/20/2026
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$10.14
3/19/2026Reiterated Rating$26.00BuyView details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 3/19/2026
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$6.81
3/19/2026Reiterated Rating$12.00BuyView details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 3/19/2026
CervoMed Inc. stock logo
CRVO
CervoMed
$3.95
3/18/2026Boost Price Target$15.00 ➝ $21.00BuyView details for Chardan Capital rating of CervoMed (NASDAQ:CRVO) on 3/18/2026
iBio, Inc. stock logo
IBIO
iBio
$1.71
3/18/2026Reiterated Rating$5.00BuyView details for Chardan Capital rating of iBio (NASDAQ:IBIO) on 3/18/2026
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$32.89
3/18/2026Reiterated Rating$35.00BuyView details for Chardan Capital rating of Stoke Therapeutics (NASDAQ:STOK) on 3/18/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$24.26
0.0%
3/17/2026Reiterated Rating$30.00BuyView details for Chardan Capital rating of Alto Neuroscience (NYSE:ANRO) on 3/17/2026
Urgent.ly Inc. stock logo
ULYX
Urgent.ly
$5.50
3/17/2026Downgrade$15.00 ➝ $5.50BuyHoldView details for Chardan Capital rating of Urgent.ly (OTCMKTS:ULYX) on 3/17/2026
VinFast Auto Ltd. stock logo
VFS
VinFast Auto
$4.31
3/17/2026Reiterated Rating$5.50BuyView details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 3/17/2026
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
$4.11
3/16/2026Reiterated Rating$14.00BuyView details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 3/16/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$121.29
3/16/2026Reiterated Rating$210.00BuyView details for Chardan Capital rating of Palvella Therapeutics (NASDAQ:PVLA) on 3/16/2026
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
$4.99
3/12/2026Boost Price Target$9.00 ➝ $11.00BuyView details for Chardan Capital rating of Opus Genetics (NASDAQ:IRD) on 3/12/2026
Orchestra BioMed Holdings, Inc. stock logo
OBIO
Orchestra BioMed
$4.04
3/12/2026Reiterated Rating$20.00BuyView details for Chardan Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 3/12/2026
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$7.27
3/12/2026Reiterated Rating$15.00BuyView details for Chardan Capital rating of Solid Biosciences (NASDAQ:SLDB) on 3/12/2026
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
$1.00
3/12/2026Reiterated Rating$8.00BuyView details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 3/12/2026
Kodiak AI, Inc. stock logo
KDK
Kodiak AI
$7.24
-0.1%
3/11/2026Reiterated Rating$22.00BuyView details for Chardan Capital rating of Kodiak AI (NASDAQ:KDK) on 3/11/2026
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$4.11
3/11/2026Boost Price Target$12.00 ➝ $14.00BuyView details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 3/11/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$17.61
3/9/2026Reiterated Rating$38.00BuyView details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 3/9/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$3.11
3/9/2026Reiterated Rating$3.50BuyView details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 3/9/2026
uniQure N.V. stock logo
QURE
uniQure
$27.66
3/9/2026Boost Price Target$16.00 ➝ $31.00BuyView details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 3/9/2026
CervoMed Inc. stock logo
CRVO
CervoMed
$3.95
3/5/2026Reiterated Rating$15.00BuyView details for Chardan Capital rating of CervoMed (NASDAQ:CRVO) on 3/5/2026
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.51
3/5/2026Reiterated Rating$7.00BuyView details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 3/5/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$13.66
3/4/2026Boost Price Target$27.00 ➝ $29.00BuyView details for Chardan Capital rating of Eyepoint Pharmaceuticals (NASDAQ:EYPT) on 3/4/2026
uniQure N.V. stock logo
QURE
uniQure
$27.66
3/3/2026Lower Price Target$53.00 ➝ $16.00BuyView details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 3/3/2026
VinFast Auto Ltd. stock logo
VFS
VinFast Auto
$4.31
3/3/2026Reiterated Rating$5.50BuyView details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 3/3/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$17.61
3/2/2026Reiterated Rating$38.00BuyView details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 3/2/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$14.09
2/27/2026Reiterated Rating$26.00BuyView details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/27/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$3.62
2/25/2026Lower Price Target$17.00 ➝ $16.00BuyView details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 2/25/2026
Allurion Technologies, Inc. stock logo
ALUR
Allurion Technologies
$0.78
2/24/2026Set Price Target$2.50 ➝ $3.00NeutralBuyView details for Chardan Capital rating of Allurion Technologies (NYSE:ALUR) on 2/24/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$121.29
2/24/2026Boost Price Target$174.00 ➝ $210.00BuyView details for Chardan Capital rating of Palvella Therapeutics (NASDAQ:PVLA) on 2/24/2026
Kodiak AI, Inc. stock logo
KDK
Kodiak AI
$7.24
-0.1%
2/19/2026Reiterated Rating$22.00BuyView details for Chardan Capital rating of Kodiak AI (NASDAQ:KDK) on 2/19/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$305.71
2/18/2026Boost Price Target$220.00 ➝ $323.00BuyView details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 2/18/2026
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$9.65
2/18/2026Reiterated Rating$21.00BuyView details for Chardan Capital rating of Ocular Therapeutix (NASDAQ:OCUL) on 2/18/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.22
2/18/2026Reiterated RatingNeutralView details for Chardan Capital rating of Oncobiologics (NASDAQ:OTLK) on 2/18/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$54.83
2/14/2026Boost Price Target$74.00 ➝ $76.00BuyView details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/14/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$295.05
2/13/2026Lower Price Target$475.00 ➝ $425.00BuyView details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 2/13/2026
iBio, Inc. stock logo
IBIO
iBio
$1.71
2/12/2026Reiterated Rating$5.00BuyView details for Chardan Capital rating of iBio (NASDAQ:IBIO) on 2/12/2026
Hyperliquid Strategies Inc stock logo
PURR
Hyperliquid Strategies
$6.71
2/12/2026Boost Price Target$8.15 ➝ $8.45BuyView details for Chardan Capital rating of Hyperliquid Strategies (NASDAQ:PURR) on 2/12/2026
Passage Bio, Inc. stock logo
PASG
Passage Bio
$4.21
2/10/2026Initiated Coverage$21.00BuyView details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 2/10/2026
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$10.55
2/10/2026Lower Price Target$52.00 ➝ $50.00BuyView details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 2/10/2026
VinFast Auto Ltd. stock logo
VFS
VinFast Auto
$4.31
2/10/2026Reiterated Rating$5.50BuyView details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 2/10/2026
Cleanspark, Inc. stock logo
CLSK
Cleanspark
$14.20
2/6/2026Lower Price Target$30.00 ➝ $16.00BuyView details for Chardan Capital rating of Cleanspark (NASDAQ:CLSK) on 2/6/2026
Korro Bio, Inc. stock logo
KRRO
Korro Bio
$12.05
1/29/2026Upgrade$15.00NeutralBuyView details for Chardan Capital rating of Korro Bio (NASDAQ:KRRO) on 1/29/2026
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
$63.58
1/29/2026Reiterated Rating$100.00BuyView details for Chardan Capital rating of Monopar Therapeutics (NASDAQ:MNPR) on 1/29/2026
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$10.55
1/29/2026Reiterated Rating$52.00BuyView details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 1/29/2026
Alumis Inc. stock logo
ALMS
Alumis
$23.66
1/21/2026Initiated Coverage$37.00BuyView details for Chardan Capital rating of Alumis (NASDAQ:ALMS) on 1/21/2026
Alumis Inc. stock logo
ALMS
Alumis
$23.66
1/21/2026Initiated Coverage$37.00BuyView details for Chardan Capital rating of Alumis (NASDAQ:ALMS) on 1/21/2026
Alumis Inc. stock logo
ALMS
Alumis
$23.66
1/21/2026Initiated Coverage$37.00BuyView details for Chardan Capital rating of Alumis (NASDAQ:ALMS) on 1/21/2026
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.51
1/20/2026Reiterated Rating$7.00BuyView details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 1/20/2026
ZOOZ Power Ltd. stock logo
ZOOZ
ZOOZ Power
$0.29
1/20/2026Initiated Coverage$2.00BuyView details for Chardan Capital rating of ZOOZ Power (NASDAQ:ZOOZ) on 1/20/2026
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
$5.83
1/13/2026Reiterated Rating$17.00BuyView details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 1/13/2026
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
$4.11
1/8/2026Reiterated Rating$14.00BuyView details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 1/8/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$72.70
+0.0%
1/7/2026Boost Price Target$60.00 ➝ $80.00BuyView details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 1/7/2026
Cleanspark, Inc. stock logo
CLSK
Cleanspark
$14.20
1/7/2026Reiterated Rating$30.00BuyView details for Chardan Capital rating of Cleanspark (NASDAQ:CLSK) on 1/7/2026
VinFast Auto Ltd. stock logo
VFS
VinFast Auto
$4.31
1/7/2026Reiterated Rating$5.50BuyView details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 1/7/2026
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$6.81
1/6/2026Reiterated Rating$12.00BuyView details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 1/6/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$24.26
0.0%
1/5/2026Boost Price Target$15.00 ➝ $30.00BuyView details for Chardan Capital rating of Alto Neuroscience (NYSE:ANRO) on 1/5/2026
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.86
1/5/2026Reiterated Rating$40.00BuyView details for Chardan Capital rating of Reviva Pharmaceuticals (NASDAQ:RVPH) on 1/5/2026
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$32.89
1/5/2026Boost Price Target$24.00 ➝ $35.00BuyView details for Chardan Capital rating of Stoke Therapeutics (NASDAQ:STOK) on 1/5/2026
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$39.59
1/2/2026Reiterated Rating$30.00BuyView details for Chardan Capital rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 1/2/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
$85.50
1/2/2026Reiterated Rating$80.00BuyView details for Chardan Capital rating of Bright Minds Biosciences (NASDAQ:DRUG) on 1/2/2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$3.60
12/24/2025Set Price Target$7.75BuyView details for Chardan Capital rating of Hyperion DeFi (NASDAQ:HYPD) on 12/24/2025
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$3.60
12/24/2025Initiated CoverageBuyView details for Chardan Capital rating of Hyperion DeFi (NASDAQ:HYPD) on 12/24/2025
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
$5.08
12/23/2025Initiated Coverage$19.00BuyView details for Chardan Capital rating of Kalaris Therapeutics (NASDAQ:KLRS) on 12/23/2025
Annexon, Inc. stock logo
ANNX
Annexon
$5.69
12/23/2025Initiated Coverage$16.00BuyView details for Chardan Capital rating of Annexon (NASDAQ:ANNX) on 12/23/2025

MarketBeat's community ratings are surveys of what our community members think about Chardan Capital and other research firms in the last 90 days. Vote "Outperform" if you believe Chardan Capital's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Chardan Capital's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days.

Log in to vote on this brokerage.
COMMUNITY RATINGS
2.6out of 5 (last 90 days)
2.6 of 5 stars
OUTPERFORM VOTES
37 Believe will outperform S&P 500
UNDERPERFORM VOTES
35 Believe will underperform S&P 500

Chardan Capital Stock Coverage by Sector

Chardan Capital concentrates its research most heavily in Medical (79.7%), Manufacturing (3.8%) and Finance (3.8%). The chart below shows how Chardan Capital's 79 rated companies are distributed across all 9 sectors it covers.

Chardan Capital - Frequently Asked Questions

Chardan Capital's analysts currently have buy-equivalent ratings on 75 companies. Recent upgrades to buy include Riot Platforms, Keel Infrastructure, Keel Infrastructure and Bradmer Pharmaceuticals.

Chardan Capital's highest-rated analysts by MarketBeat's accuracy score include Daniil Gataulin, Geulah Livshits and Keay Nakae. Rankings are based on historical rating accuracy and price target precision over the past 12 months. MarketBeat tracks 7 analysts at Chardan Capital.

Chardan Capital has the deepest coverage in Medical (79.7% of rated companies), Finance (3.8% of rated companies), Manufacturing (3.8% of rated companies), Computer and Technology (2.5% of rated companies) and Financial Services (1.3% of rated companies).

Chardan Capital issued 306 ratings over the last 12 months across 79 companies — an average of roughly 26 rating actions per month. These include boost price target, downgrade, initiated coverage, lower price target, reiterated rating, set price target and upgrade. MarketBeat tracks every rating change as it's published so you can see the most current Chardan Capital analyst actions.

A buy rating indicates the analyst expects the stock to outperform the market over the next 12 months. A hold suggests the stock will perform in line with the market. A sell rating indicates expected underperformance. Chardan Capital uses Buy, Neutral, and Sell as their equivalents.